Advertisement

Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction

      Patients with heart failure with preserved ejection fraction (HFpEF) have few pharmacologic therapies, and it is not known if supplementing with ubiquinol and/or d-ribose could improve outcomes. The overall objective of this study was to determine if ubiquinol and/or d-ribose would reduce the symptoms and improve cardiac performance in patients with HFpEF. This was a phase 2 randomized, double-blind, placebo-controlled trial of 216 patients with HFpEF who were ≥ 50 years old with a left ventricular ejection fraction (EF) ≥ 50%. A total of 4 study groups received various supplements over 12 weeks: Group 1 received placebo ubiquinol capsules and d-ribose powder, Group 2 received ubiquinol capsules (600 mg/d) and placebo d-ribose powder, Group 3 received placebo ubiquinol capsules with d-ribose powder (15 g/d), and Group 4 received ubiquinol capsules and d-ribose powder. There were 7 outcome measures for this study: Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score, level of vigor using a subscale from the Profile of Mood States, EF, the ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity (septal E/e’ ratio), B-type natriuretic peptides, lactate/adenosine triphosphate ratio, and the 6-minute walk test. Treatment with ubiquinol and/or d-ribose significantly improved the KCCQ clinical summary score (17.30 to 25.82 points), vigor score (7.65 to 8.15 points), and EF (7.08% to 8.03%) and reduced B-type natriuretic peptides (−72.02 to −47.51) and lactate/adenosine triphosphate ratio (−4.32 to −3.35 × 10−4). There were no significant increases in the septal E/e′ or the 6-minute walk test. In conclusion, ubiquinol and d-ribose reduced the symptoms of HFpEF and increased the EF. These findings support the use of these supplements in addition to standard therapeutic treatments for patients with HFpEF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Obokata M
        • Reddy YNV
        • Borlaug BA.
        Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods.
        JACC Cardiovasc Imaging. 2020; 13: 245-257
        • Oren O
        • Goldberg S.
        Heart failure with preserved ejection fraction: diagnosis and management.
        Am J Med. 2017; 130: 510-516
        • Pierce JD
        • Mahoney DE
        • Hiebert JB
        • Thimmesch AR
        • Diaz FJ
        • Smith C
        • Shen Q
        • Mudaranthakam DP
        • Clancy RL.
        Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or d-ribose.
        BMC Cardiovasc Disord. 2018; 18: 57
      1. Statistical analysis system (SAS); 2021. Available at:https://www.sas.com/en_us/curiosity.html?utm_source=other&utm_medium=cpm&utm_campaign=non-cbo-us&dclid=&gclid=EAIaIQobChMIg9L6yt3w9gIVA2xvBB39FAQ7EAAYASAAEgKRMfD_BwE. Accessed February 8, 2022.

        • Onur S
        • Niklowitz P
        • Jacobs G
        • Lieb W
        • Menke T
        • Döring F.
        Association between serum level of ubiquinol and nt-probnp, a marker for chronic heart failure, in healthy elderly subjects.
        BioFactors. 2015; 41: 35-43
        • Kalén A
        • Appelkvist EL
        • Dallner G.
        Age-related changes in the lipid compositions of rat and human tissues.
        Lipids. 1989; 24: 579-584
        • Mortensen SA
        • Rosenfeldt F
        • Kumar A
        • Dolliner P
        • Filipiak KJ
        • Pella D
        • Alehagen U
        • Steurer G
        • Littarru GP
        • Q-SYMBIO Study Investigators
        The effect of coenzyme q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
        JACC Heart Fail. 2014; 2: 641-649
        • Mortensen AL
        • Rosenfeldt F
        • Filipiak KJ.
        Effect of coenzyme q10 in Europeans with chronic heart failure: a sub-group analysis of the q-symbio randomized double-blind trial.
        Cardiol J. 2019; 26: 147-156
        • Bayram M
        • St Cyr JA
        • Abraham WT
        D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study.
        Ther Adv Cardiovasc Dis. 2015; 9: 56-65
        • Pliml W
        • von Arnim T
        • Stäblein A
        • Hofmann H
        • Zimmer HG
        • Erdmann E.
        Effects of ribose on exercise-induced ischaemia in stable coronary artery disease.
        Lancet. 1992; 340: 507-510
        • Derosa G
        • Pasqualotto S
        • Catena G
        • D'Angelo A
        • Maggi A
        • Maffioli P
        A randomized, double-blind, placebo-controlled study to evaluate the effectiveness of a food supplement containing creatine and d-ribose combined with a physical exercise program in increasing stress tolerance in patients with ischemic heart disease.
        Nutrients. 2019; 11
        • Ingwall JS
        • Weiss RG.
        Is the failing heart energy starved? On using chemical energy to support cardiac function.
        Circ Res. 2004; 95: 135-145
        • Huang W
        • Teng TK
        • Tay WT
        • Richards AM
        • Kadam U
        • Lawson CA
        • Shimizu W
        • Loh SY
        • Anand I
        • Lam CSP.
        Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence.
        ESC Heart Fail. 2020; 7: 2051-2062
        • Pokharel Y
        • Khariton Y
        • Tang Y
        • Nassif ME
        • Chan PS
        • Arnold SV
        • Jones PG
        • Spertus JA.
        Association of serial kansas city cardiomyopathy questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials.
        JAMA Cardiol. 2017; 2: 1315-1321
        • Deaton C
        • Forsyth F
        • Mant J
        • Edwards D
        • Hobbs R
        • Taylor C
        • Aziz A
        • Schiff R
        • Odone J
        • Zaman J.
        Characteristics and health status of patients with and without confirmed HFpEF.
        Eur Heart J. 2020; 41: 3139
        • Fink AM
        • Eckhardt AL
        • Fennessy MM
        • Jones J
        • Kruse D
        • VanderZwan KJ
        • Ryan CJ
        • Zerwic JJ.
        Psychometric properties of three instruments to measure fatigue with myocardial infarction.
        West J Nurs Res. 2010; 32: 967-983
        • Fukuoka Y
        • Lindgren TG
        • Rankin SH
        • Cooper BA
        • Carroll DL.
        Cluster analysis: a useful technique to identify elderly cardiac patients at risk for poor quality of life.
        Qual Life Res. 2007; 16: 1655-1663
        • Fennessy MM
        • Fink AM
        • Eckhardt AL
        • Jones J
        • Kruse DK
        • VanderZwan KJ
        • Ryan CJ
        • Zerwic JJ.
        Gender differences in fatigue associated with acute myocardial infarction.
        J Cardiopulm Rehabil Prev. 2010; 30: 224-230
        • Kawashima C
        • Matsuzawa Y
        • Konishi M
        • Akiyama E
        • Suzuki H
        • Sato R
        • Nakahashi H
        • Kikuchi S
        • Kimura Y
        • Maejima N
        • Iwahashi N
        • Hibi K
        • Kosuge M
        • Ebina T
        • Tamura K
        • Kimura K.
        Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study.
        Am J Cardiovasc Drugs. 2020; 20: 363-372
        • Kumar A
        • Singh RB
        • Saxena M
        • Niaz MA
        • Josh SR
        • Chattopadhyay P
        • Mechirova V
        • Pella D
        • Fedacko J.
        Effect of carni q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the tishcon study.
        Acta Cardiol. 2007; 62: 349-354
        • Sander S
        • Coleman CI
        • Patel AA
        • Kluger J
        • White CM.
        The impact of coenzyme q10 on systolic function in patients with chronic heart failure.
        J Card Fail. 2006; 12: 464-472
        • Samuel TY
        • Hasin T
        • Gotsman I
        • Weitzman T
        • Ben Ivgi F
        • Dadon Z
        • Asher E
        • Amir O
        • Glikson M
        • Alcalai R
        • Leibowitz D
        Coenzyme q10 in the treatment of heart failure with preserved ejection fraction: a prospective, randomized, double-blind, placebo-controlled trial.
        Drugs R D. 2022; 22: 25-33
        • Vijay N
        • MacCarter D
        • Shecterle LM
        • St Cyr JA
        D-ribose benefits heart failure patients.
        J Med Food. 2008; 11: 199-200
        • Dai DF
        • Chen T
        • Szeto H
        • Nieves-Cintrón M
        • Kutyavin V
        • Santana LF
        • Rabinovitch PS.
        Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy.
        J Am Coll Cardiol. 2011; 58: 73-82
        • Phan TT
        • Abozguia K
        • Nallur Shivu G
        • Mahadevan G
        • Ahmed I
        • Williams L
        • Dwivedi G
        • Patel K
        • Steendijk P
        • Ashrafian H
        • Henning A
        • Frenneaux M
        Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency.
        J Am Coll Cardiol. 2009; 54: 402-409
        • Chida J
        • Kido H.
        Extraction and quantification of adenosine triphosphate in mammalian tissues and cells.
        Methods Mol Biol. 2014; 1098: 21-32
        • Chida J
        • Ono R
        • Yamane K
        • Hiyoshi M
        • Nishimura M
        • Onodera M
        • Nakataki E
        • Shichijo K
        • Matushita M
        • Kido H.
        Blood lactate/atp ratio, as an alarm index and real-time biomarker in critical illness.
        PLOS ONE. 2013; 8: e60561
        • Wolsk E
        • Kaye D
        • Borlaug BA
        • Burkhoff D
        • Kitzman DW
        • Komtebedde J
        • Lam CSP
        • Ponikowski P
        • Shah SJ
        • Gustafsson F.
        Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction.
        Eur J Heart Fail. 2018; 20: 715-722
        • Witte KK
        • Byrom R
        • Gierula J
        • Paton MF
        • Jamil HA
        • Lowry JE
        • Gillott RG
        • Barnes SA
        • Chumun H
        • Kearney LC
        • Greenwood JP
        • Plein S
        • Law GR
        • Pavitt S
        • Barth JH
        • Cubbon RM
        • Kearney MT.
        Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE study.
        J Am Coll Cardiol. 2016; 67: 2593-2603
        • Roell KR
        • Reif DM
        • Motsinger-Reif AA.
        An introduction to terminology and methodology of chemical synergy-perspectives from across disciplines.
        Front Pharmacol. 2017; 8: 158